Sandu [SANDUPHQ] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Sandu
BSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sandu wins in 8 metrics, Divi's Laboratories wins in 12 metrics, with 0 ties. Divi's Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sandu | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.81 | 65.37 | Sandu |
| Price-to-Book Ratio | 1.05 | 10.13 | Sandu |
| Debt-to-Equity Ratio | 1.14 | 0.03 | Divi's Laboratories |
| PEG Ratio | 0.79 | 2.47 | Sandu |
| EV/EBITDA | 14.56 | 48.31 | Sandu |
| Profit Margin (TTM) | 2.41% | 23.89% | Divi's Laboratories |
| Operating Margin (TTM) | 2.08% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | 2.08% | 25.60% | Divi's Laboratories |
| Return on Equity | 3.69% | 14.64% | Divi's Laboratories |
| Return on Assets (TTM) | 2.78% | 12.94% | Divi's Laboratories |
| Free Cash Flow (TTM) | $104,000 | $2.15B | Divi's Laboratories |
| Dividend Yield | 1.61% | 0.91% | Sandu |
| 1-Year Return | -22.09% | 8.12% | Divi's Laboratories |
| Price-to-Sales Ratio (TTM) | 0.67 | 15.71 | Sandu |
| Enterprise Value | $426.40M | $1,480.60B | Divi's Laboratories |
| EV/Revenue Ratio | 0.64 | 15.34 | Sandu |
| Gross Profit Margin (TTM) | 47.10% | 60.33% | Divi's Laboratories |
| Revenue per Share (TTM) | $69 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | $1.66 | $87.36 | Divi's Laboratories |
| Beta (Stock Volatility) | 0.17 | 0.18 | Sandu |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sandu vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sandu | 0.26% | -0.13% | -3.60% | -7.75% | -4.91% | -17.81% |
| Divi's Laboratories | 2.73% | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sandu | -22.09% | -33.31% | 42.40% | 36.12% | 219.17% | 98.20% |
| Divi's Laboratories | 8.12% | 57.02% | 83.89% | 435.51% | 1,516.65% | 7,132.15% |
News Based Sentiment: Sandu vs Divi's Laboratories
Sandu
News based Sentiment: NEGATIVE
September was a significantly negative month for Sandu Pharmaceuticals, characterized by a consistent decline in stock price, a shift in valuation to 'fair', and the first revenue contraction in three years. These developments, coupled with a notable stake sale and declining investor participation, create a concerning picture for investors and suggest a challenging period ahead for the company.
Divi's Laboratories
News based Sentiment: MIXED
September presented a mixed bag for Divi's Laboratories, with stellar FY25 results overshadowed by a weaker Q1 FY26 performance and fluctuating analyst opinions. The Nifty 50 exclusion adds another layer of complexity, creating a dynamic investment scenario that requires careful monitoring.
Performance & Financial Health Analysis: Sandu vs Divi's Laboratories
| Metric | SANDUPHQ | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹461.45M | ₹1.61T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,224 | 437,716 |
| 90 Day Avg. Volume | 1,326 | 381,180 |
| Last Close | ₹46.28 | ₹5,866.00 |
| 52 Week Range | ₹43.75 - ₹62.80 | ₹4,955.00 - ₹7,071.50 |
| % from 52W High | -26.31% | -17.05% |
| All-Time High | ₹86.00 (Apr 25, 2022) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -46.19% | -17.05% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.14% |
| Quarterly Earnings Growth | 0.34% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.24% |
| Operating Margin (TTM) | 0.02% | 0.26% |
| Return on Equity (TTM) | 0.04% | 0.15% |
| Debt to Equity (MRQ) | 1.14 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹43.77 | ₹563.87 |
| Cash per Share (MRQ) | ₹2.73 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹5.35M | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹15.52M | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.61% | 0.91% |
| Last 12-Month Dividend | ₹0.80 | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Sandu vs Divi's Laboratories
| Metric | SANDUPHQ | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.81 | 65.37 |
| Forward P/E | N/A | 101.43 |
| PEG Ratio | 0.79 | 2.47 |
| Price to Sales (TTM) | 0.67 | 15.71 |
| Price to Book (MRQ) | 1.05 | 10.13 |
| Market Capitalization | ||
| Market Capitalization | ₹461.45M | ₹1.61T |
| Enterprise Value | ₹426.40M | ₹1.48T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.64 | 15.34 |
| Enterprise to EBITDA | 14.56 | 48.31 |
| Risk & Other Metrics | ||
| Beta | 0.17 | 0.18 |
| Book Value per Share (MRQ) | ₹43.77 | ₹563.87 |
Financial Statements Comparison: Sandu vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANDUPHQ | DIVISLAB |
|---|---|---|
| Revenue/Sales | ₹166.99M | ₹24.10B |
| Cost of Goods Sold | ₹88.33M | ₹9.56B |
| Gross Profit | ₹78.66M | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹3.48M | ₹6.17B |
| EBITDA | ₹5.43M | ₹8.48B |
| Pre-Tax Income | ₹3.39M | ₹7.33B |
| Income Tax | ₹1.15M | ₹1.88B |
| Net Income (Profit) | ₹2.23M | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANDUPHQ | DIVISLAB |
|---|---|---|
| Cash & Equivalents | ₹13.04M | ₹4.15B |
| Total Current Assets | ₹262.99M | ₹100.81B |
| Total Current Liabilities | ₹120.86M | ₹14.52B |
| Long-Term Debt | ₹4.19M | ₹20.00M |
| Total Shareholders Equity | ₹420.17M | ₹149.69B |
| Retained Earnings | ₹95.24M | ₹134.00B |
| Property, Plant & Equipment | ₹7.46M | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANDUPHQ | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANDUPHQ | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,224 | 437,716 |
| Average Daily Volume (90 Day) | 1,326 | 381,180 |
| Shares Outstanding | 9.66M | 265.47M |
| Float Shares | 3.24M | 120.77M |
| % Held by Insiders | 0.66% | 0.52% |
| % Held by Institutions | 0.00% | 0.29% |
Dividend Analysis & Yield Comparison: Sandu vs Divi's Laboratories
| Metric | SANDUPHQ | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | ₹0.80 | ₹60.00 |
| Last 12-Month Dividend Yield | 1.61% | 0.91% |
| 3-Year Avg Annual Dividend | ₹1.02 | ₹50.00 |
| 3-Year Avg Dividend Yield | 1.12% | 0.70% |
| 3-Year Total Dividends | ₹3.05 | ₹150.00 |
| Ex-Dividend Date | Sep 19, 2024 | Jul 25, 2025 |